The Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act, has gone through three selection cycles (2023–2026), and in this policy brief, IVI argues CMS should anchor negotiated prices in broader patient-centered value—not just lower costs—while embedding equity, transparency, and real-world evidence into impplementation.
